Stockscreener 앱 받기
35.80
1.79%
0.63
시간 외 거래:
37.06
1.26
+3.52%
전일 마감가:
$35.17
열려 있는:
$35.17
하루 거래량:
325.04K
Relative Volume:
1.03
시가총액:
$1.61B
수익:
$45.95M
순이익/손실:
$-48.88M
주가수익비율:
-32.17
EPS:
-1.1129
순현금흐름:
$109.67M
1주 성능:
+17.49%
1개월 성능:
+32.84%
6개월 성능:
+34.84%
1년 성능:
+249.61%
1일 변동 폭
$33.88
$36.12
1주일 범위
$30.74
$37.01
52주 변동 폭
$9.8515
$37.01
Septerna Inc Stock (SEPN) Company Profile
명칭
Septerna Inc
전화
650-338-3533
주소
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
35.80 | 1.62B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | Raymond James | Strong Buy |
| 2025-12-15 | 개시 | Truist | Buy |
| 2025-11-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-06-23 | 개시 | H.C. Wainwright | Buy |
| 2025-02-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-19 | 개시 | JP Morgan | Overweight |
| 2024-11-19 | 개시 | TD Cowen | Buy |
| 2024-11-19 | 개시 | Wells Fargo | Overweight |
모두보기
Septerna Inc 주식(SEPN)의 최신 뉴스
Septerna Inc. (SEPN) Jumps 5.6% as Shares Test Key Resistance LevelVolatility Term Structure - newsline.com
SEPN Q1 2026 Earnings: Narrower Loss Beats Expectations, Shares RiseProfit Margin Analysis - newsline.com
SEPN: 8,428 shares proposed sale; Samira Shaikhly 10b5-1 sales listed - Stock Titan
Septerna (SEPN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Guggenheim Initiates Septerna at Buy With $52 Price Target - Moomoo
Septerna Inc stock reaches all-time high at 32.76 USD - Investing.com
Did SEP-479’s Endocrine Society Spotlight Just Shift Septerna’s (SEPN) Hypoparathyroidism Investment Narrative? - simplywall.st
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting - Lelezard
Raymond James raises Septerna stock price target on pipeline potential - Investing.com UK
Experimental oral hypoparathyroidism drug SEP-479 gets ENDO 2026 stage - Stock Titan
Raymond James raises Septerna stock price target on pipeline potential By Investing.com - Investing.com Australia
Raymond James Maintains Septerna(SEPN.US) With Buy Rating, Raises Target Price to $53 - Moomoo
SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Septerna’s chief people officer sells $171,682 in stock By Investing.com - Investing.com Australia
Septerna’s chief people officer sells $171,682 in stock - Investing.com
Septerna (SEPN) CPO sells 5,935 shares under Rule 10b5-1 plan - Stock Titan
SEPN Q1 2026 Earnings: Smaller-Than-Expected Loss Reflects Operational DisciplineNegative Surprise Momentum - newsline.com
Septerna Inc. (SEPN) Slips 2.74% as Stock Tests Key Support LevelsContinuation Pattern Picks - The Legal Advocate
Septerna chief people officer Samira Shaikhly sells $354,656 common stock By Investing.com - Investing.com South Africa
Septerna Inc. (SEPN) Faces Pressure: Key Support Levels in Focus Amid 3.77% DeclineAndrews Pitchfork - The Legal Advocate
SEPN Q1 2026 Earnings: EPS Beat Drives Optimism Amid Pre-Revenue PhaseProfit Growth Outlook - newsline.com
Septerna (SEPN) Chief People Officer exercises options and sells 11,798 shares - Stock Titan
Septerna chief people officer Samira Shaikhly sells $354,656 common stock - Investing.com
Septerna Inc. (SEPN) Surges 8% as Bullish Momentum BuildsSentiment Shift - The Legal Advocate
SEPN (NASDAQ: SEPN) option exercise sale of 11,798 shares on 05/26/2026 - Stock Titan
3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026 - TipRanks
Septerna Inc. Q1 2026 Earnings: Narrower‑Than‑Expected Loss Boosts Investor SentimentGuidance Upgrade Report - The Legal Advocate
SEPN Q1 2026 Earnings: Smaller-Than-Expected Loss Amidst Pipeline ProgressEarnings Revision Downgrade - Newser
SEPN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineExpert Momentum Signals - Newser
Septerna Inc. (SEPN) Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Market ResponseCommunity Pattern Alerts - Newser
Septerna Inc. (SEPN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineROA Comparison - Newser
New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN) - Sahm
Septerna, Inc. (SEPN) Competitors - Meyka
Septerna (SEPN) Q1 2026 Crushes Forecasts — EPS $-0.19 vs $-0.42Free Stock Community - Newser
Why Septerna (SEPN) Is Up 11.6% After Q1 Revenue Surge And Narrowed Losses - simplywall.st
Party Time: Brokers Just Made Major Increases To Their Septerna, Inc. (NASDAQ:SEPN) Earnings Forecasts - Yahoo Finance
Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Q2 Earnings Forecast for Septerna Issued By HC Wainwright - MarketBeat
Septerna Inc (SEPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Septerna Inc 주식 (SEPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shaikhly Samira | Chief People Officer |
Jun 12 '26 |
Sale |
35.08 |
6,250 |
219,224 |
793 |
2.60%
0.94%
자본화:
|
볼륨(24시간):